Laigaard J, Bache N, Stottmeier S, et al. - In this prospective cohort study, researchers sought to examine the cognitive function and health-related quality of life in patients with chronic non-cancer pain during opioid reduction. All individuals with planned opioid reduction were screened for eligibility at two multidisciplinary pain centers. Using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Trail Making Test A and B, cognitive function was evaluated. Using Short Form-36 (SF36) and Hospital Anxiety and Depression Scale (HADS), health-related quality of life was evaluated. Fifty-one participants were included and 40 participants attended a median follow-up of 254 days. For Trail Making Test times, HADS or SF36 scores, no differences were found. Generally, after opioid tapering with stationary health-related quality of life, depression and anxiety scores, cognitive function showed minor improvement. The clinical significance is uncertain, as there is no minimal clinically meaningful difference available in the RBANS score.